NCT03739593 - Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

May 14, 2020

Study Completion Date

July 9, 2020

Conditions

Macular Edema

Interventions

DRUG

AR-1105-CF1

AR-1105 clinical formulation 1 (AR-1105-CF1)

DRUG

AR-1105-CF2

AR-1105 clinical formulation 2 (AR-1105-CF2)

Trial Locations (11)

Retina Specialty Institute, Pensacola

Florida Eye Clinic, Altamonte Springs

Center for Retina & Macular Disease, Lakeland

Cleveland Clinic- Cole Eye Institute, Cleveland

Texas Retina Associates, Arlington

Medical Center Ophthalmology Associates, San Antonio

Retina Research Institute of Texas, Abilene

Retinal Research Institute, LLC, Phoenix

Retina Vitreous Associates, Beverly Hills

Byers Eye Institute at Stanford, Palo Alto

Mid-Atlantic Retina, Cherry Hill